8-K: CEL-SCI's Multikine Shows Strong 5-Year Survival Rate in Head and Neck Cancer Study

CEL-SCI reported that its Multikine treatment increased the 5-year survival rate to 82.6% in a specific group of head and neck cancer patients, with a 73% reduction in the risk of death.

Summary

• CEL-SCI Corporation announced new data from its Phase 3 study of Multikine, presented at the European Society for Medical Oncology (ESMO) 2024 Congress.
• The data showed a 5-year survival rate of 82.6% for a subset of patients with locally advanced resectable head and neck cancer who were treated with Multikine and were deemed low risk for recurrence.
• This group also experienced a 73% reduction in the overall risk of death, with a hazard ratio of 0.27.
• The results are based on a further analysis of 114 patients from the Phase 3 study who met the criteria for the upcoming confirmatory Registration Study.
• The confirmatory study will focus on patients with newly diagnosed locally advanced primary head and neck cancer with no lymph node involvement and low PD-L1 tumor expression.
• The FDA has given the go-ahead for this 212-patient confirmatory Registration Study, which is currently under preparation.
• The original Phase 3 study of 923 patients showed a median overall survival benefit of 46.5 months for patients deemed low risk for recurrence after surgery who were treated with Multikine.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with a significant improvement in survival rates and a substantial reduction in the risk of death. The management commentary is also optimistic, and the company is moving forward with a confirmatory study. The only negative is that the treatment is still investigational.

Positives

• The 82.6% 5-year survival rate is a significant improvement compared to the standard of care, which has a survival rate below 50% for similar patients.
• The 73% reduction in the risk of death is a substantial benefit for patients treated with Multikine.
• The data suggests that Multikine is particularly effective for patients who are not scheduled to receive chemotherapy after surgery.
• The upcoming confirmatory Registration Study is focused on the patient population that showed the greatest benefit from Multikine.
• The use of PET scans in the confirmatory study may further optimize patient selection and improve outcomes.

Negatives

• The original Phase 3 study showed no survival benefit for patients who were deemed high risk for recurrence and received chemotherapy after surgery.
• Multikine is still an investigational therapy and has not been approved for sale by the FDA or any other regulatory agency.
• The safety and efficacy of Multikine have not been established for any use.

Risks

• There is a risk that the clinical results demonstrated in the Phase 3 study may not be duplicated in future studies.
• The company may face challenges in the timely development of a safe and effective product.
• There is a risk that the company may not receive necessary regulatory approvals.
• The company may face difficulties in manufacturing its potential products.
• The company may be unable to raise the necessary capital to continue development.

Future Outlook

The company is preparing for a 212-patient confirmatory Registration Study, which will focus on a specific patient population that showed the greatest benefit from Multikine. The study will use PET scans for improved patient selection.

Management Comments

• CEL-SCI CEO Geert Kersten stated that the data provides further evidence that they have identified the target population that has the greatest survival benefit from Multikine.
• He also noted that Multikine, an immunotherapy, provides greater benefit to patients who are not scheduled to receive chemotherapy.
• CEL-SCI's CSO Eyal Talor, Ph.D. commented that the criteria developed for selecting patients showed an overall survival advantage with Multikine treatment.

Industry Context

The results are significant in the context of head and neck cancer treatment, where the 5-year survival rate remains below 50% for patients receiving standard of care only. The study suggests that Multikine could offer a substantial improvement in survival rates for a specific patient population.

Comparison to Industry Standards

• The 5-year survival rate of 82.6% for the Multikine treated group is significantly higher than the typical 5-year survival rate of below 50% for locally advanced resectable head and neck cancer patients receiving standard of care.
• Key competitors in the head and neck cancer treatment space include companies developing chemotherapy regimens, radiation therapies, and other immunotherapies. However, the specific patient selection criteria and the magnitude of the survival benefit reported for Multikine appear to be unique.
• The hazard ratio of 0.27 indicates a substantial reduction in the risk of death compared to standard treatments, which typically have hazard ratios closer to 1.0.
• The use of PET scans for patient selection in the confirmatory study is a step towards personalized medicine, which is a growing trend in oncology.

Stakeholder Impact

• Shareholders may view the results positively, potentially leading to an increase in the company's stock price.
• Patients with head and neck cancer may have a new treatment option with a potentially higher survival rate.
• Employees may be motivated by the positive results and the potential for the company's success.
• The company's suppliers and partners may benefit from the increased activity and potential growth.

Next Steps

• CEL-SCI will conduct a 212-patient confirmatory Registration Study.
• The confirmatory study will focus on patients with newly diagnosed locally advanced primary head and neck cancer with no lymph node involvement and low PD-L1 tumor expression.
• The study will use PET scans for improved patient selection.

Key Dates

Keywords

Multikine, head and neck cancer, immunotherapy, survival rate, Phase 3 study, clinical trial, FDA, ESMO, cancer treatment, oncology